Most Popular Stories
Featured Jobs
-
Epic Ambulatory Beacon Consultant
Meditology Services - NC -
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA
Events
- IHI's Breakthrough Series College
April 11-13, 2012 — Cambridge, MA - CIO Healthcare Summit
March 11-14 — Scottsdale, AZ - Wharton Health Care Business Conference
Feb 16-17 — Philadelphia, PA - 3rd Healthcare IT Innovation Asia
Mar 14-15 2012 — Singapore
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
Forest accused of hiding negative Celexa, Lexapro results
The U.S. Department of Justice has filed a complaint against Forest Laboratories, the maker of antidepressants Celexa and Lexapro, accusing it of being underhanded in how it disclosed its research.
The DOJ is arguing that the company hid the results of a study suggesting that the medications didn't work for children and might even increase the risk of their becoming suicidal, while playing up other more-positive study results. The DOJ's complaint also asserts that Forest offered kickbacks to doctors who prescribed the drugs and promoted them for unapproved uses.
Apparently, the company submitted both positive and negative study results to the FDA in 2002. The agency rejected pediatric approval for Celexa, predecessor to Lexapro, based on the negative results presented. However, as is standard practice, the FDA didn't disclose what Forest had submitted.
To learn more about this story:
- read this piece in the New York Times
Related Articles:
Rising teen suicides may be linked to lower antidepressant use
Senate to investigate Brown University psychiatrist
Related Stories
- Federal prosecutors: Psychiatrist paid to tout off-label antidepressant use
- No mandatory antitrust review for ACOs
- Legal hurdles in ACO process to dissuade participants
- Hospitals running out of drugs, seeking medication alternatives
- Blood test helps prevent serious contrast-agent complications
- House committee approves medical liability reform
- Lax regulation of tube design harms patients
- Doctor duped more than 100 chronically ill patients in stem-cell scam
- New knowledge of radiation risks prompts FDA, providers to make changes
- FDA looking to reduce radiation exposure to patients
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
